A new survey of 47 healthcare C-suite executives found that drug spending has increased among healthcare leaders. That trend, the report’s authors say, will only increase in the coming years, and health system leaders will need strategies to cope with the burden.
A new survey of 47 healthcare C-suite executives (including CEOs, CFOs, CMOs, and others) conducted by Premier Inc. found that drug spending has increased among healthcare leaders. That trend, the report’s authors say, will only increase in the coming years, and health system leaders will need strategies to cope with the burden.
According to 96% of the C-suite respondents, their hospitals or health systems had either “somewhat increased” or “significantly increased” their overall pharmacy spending, and 95% reported that they had experienced higher drug prices. More expensive specialty drugs were identified as primary contributors to organizations’ pharmaceutical spending by 91% of those surveyed.
To help manage rising costs, 89% of respondents said they expanded use of generic drugs if available, while 82% said that they had tightened their formularies. Pharmacists were called upon by 75% of respondents to provide guidance on expensive drug use patterns and to discuss therapeutically equivalent alternatives, and 75% of those surveyed had educated physicians in drug use management and cost-savings measures, encouraging providers to use generics and higher-value therapeutic alternatives to costly drugs.
A much lower percentage (59%) of C-suite leaders reported using generics for automatic substitution. Fewer still had adopted biosimilars—only 55% of respondents indicated that they had used available biosimilar treatments as alternatives to more expensive reference products.
When asked to estimate the rise in drug prices over the coming 5 years, 95% of those surveyed believed that prices could jump by over 10%, while 16% estimated that prices could climb by at least 30%.
Michael J. Alkire, COO of Premier Inc, said,“Healthcare leaders must think creatively and optimize prescribing methods to ensure a positive outcome at a manageable cost.”
With a growing biosimilar pipeline, and with the potential for payers and patients alike to realize cost savings through the use of biosimilar therapies, one such strategy that leaders may adopt is greater provider education in the use of biosimilars as alternatives to costly biologics.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.